BC Extra | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
BioCentury | May 3, 2019
Emerging Company Profile

Vineti: Keeping cell therapies on track

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines. According to Vineti Inc. CEO...
BC Extra | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BC Extra | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
BC Week In Review | Sep 28, 2018
Company News

Tessa, St. Jude partner to develop cellular immunotherapies for pediatric brain cancers

Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat pediatric brain cancers using Tessa's virus-specific T cell technology. Using Tessa's technology, a patient's cytotoxic...
BC Week In Review | Apr 13, 2018
Financial News

Tessa gets extra $50M, adds Goran Ando to board

Immunotherapy company Tessa Therapeutics Pte. Ltd. (Singapore) added $50 million to a financing round announced in December, bringing the round's total to $130 million. The company also named former Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) Chairman...
BC Extra | Apr 12, 2018
Financial News

Tessa raises additional $50M, names Ando to board

Immunotherapy company Tessa Therapeutics Pte. Ltd. (Singapore) added $50 million to a financing round announced in December, bringing the round's total to $130 million. The company also named former Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) Chairman...
BC Week In Review | Dec 22, 2017
Financial News

Tessa raises $80M in financing

On Dec. 20, Tessa Therapeutics Pte. Ltd. (Singapore) raised $80 million in an undisclosed financing round led by Temasek. EDBI, Karst Peak Capital, Heliconia and Heritas also participated. Tessa is developing an oncology focused pipeline...
BC Extra | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
BC Extra | Jul 21, 2017
Company News

Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO while the company seeks Lowe's successor. Neurology and cardiovascular company...
Items per page:
1 - 10 of 12
BC Extra | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
BioCentury | May 3, 2019
Emerging Company Profile

Vineti: Keeping cell therapies on track

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines. According to Vineti Inc. CEO...
BC Extra | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BC Extra | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
BC Week In Review | Sep 28, 2018
Company News

Tessa, St. Jude partner to develop cellular immunotherapies for pediatric brain cancers

Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat pediatric brain cancers using Tessa's virus-specific T cell technology. Using Tessa's technology, a patient's cytotoxic...
BC Week In Review | Apr 13, 2018
Financial News

Tessa gets extra $50M, adds Goran Ando to board

Immunotherapy company Tessa Therapeutics Pte. Ltd. (Singapore) added $50 million to a financing round announced in December, bringing the round's total to $130 million. The company also named former Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) Chairman...
BC Extra | Apr 12, 2018
Financial News

Tessa raises additional $50M, names Ando to board

Immunotherapy company Tessa Therapeutics Pte. Ltd. (Singapore) added $50 million to a financing round announced in December, bringing the round's total to $130 million. The company also named former Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) Chairman...
BC Week In Review | Dec 22, 2017
Financial News

Tessa raises $80M in financing

On Dec. 20, Tessa Therapeutics Pte. Ltd. (Singapore) raised $80 million in an undisclosed financing round led by Temasek. EDBI, Karst Peak Capital, Heliconia and Heritas also participated. Tessa is developing an oncology focused pipeline...
BC Extra | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
BC Extra | Jul 21, 2017
Company News

Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO while the company seeks Lowe's successor. Neurology and cardiovascular company...
Items per page:
1 - 10 of 12